Ixotatug vedotin

N/A

Report date: 2026/04/16 20:00:17
First In Class

Base Information

Drug NameIxotatug vedotin
Drug Alias NameTORL-1-23
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN6Tubulin polymerisation inhibitors
TargetsClaudin 6Tubulin
Therapy Area/IndicationsSolid tumoursFallopian Tube DiseasesPeritoneal Diseases +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTorl Biotherapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesTorl Biotherapeutics LLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursFallopian Tube DiseasesPeritoneal Diseases +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A